Dr. Akce noted that FLOT surpassed pre‑op chemoradiotherapy in resectable esophageal/GE cancers (SOPHEC), perioperative chemo + durvalumab extended event‑free survival in gastric/GE junction adenocarcinoma (MATTERHORN), and adjuvant nivolumab stayed advantageous after resection (CheckMate 577). He added that metastatic gastric cancer now favors chemo‑immunotherapy for CPS ≥1, with zolbetuximab improving PFS and trastuzumab deruxtecan benefiting HER2‑positive disease, while supportive measures like aspirin and structured exercise are under consideration.